• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

tetano

Editor, Senior Moderator
Cell


. 2020 Nov 23;S0092-8674(20)31565-8.
doi: 10.1016/j.cell.2020.11.029. Online ahead of print.
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19


Lauren B Rodda[SUP] 1 [/SUP], Jason Netland[SUP] 1 [/SUP], Laila Shehata[SUP] 1 [/SUP], Kurt B Pruner[SUP] 1 [/SUP], Peter A Morawski[SUP] 2 [/SUP], Christopher D Thouvenel[SUP] 3 [/SUP], Kennidy K Takehara[SUP] 1 [/SUP], Julie Eggenberger[SUP] 4 [/SUP], Emily A Hemann[SUP] 4 [/SUP], Hayley R Waterman[SUP] 2 [/SUP], Mitchell L Fahning[SUP] 2 [/SUP], Yu Chen[SUP] 3 [/SUP], Malika Hale[SUP] 3 [/SUP], Jennifer Rathe[SUP] 4 [/SUP], Caleb Stokes[SUP] 4 [/SUP], Samuel Wrenn[SUP] 5 [/SUP], Brooke Fiala[SUP] 5 [/SUP], Lauren Carter[SUP] 5 [/SUP], Jessica A Hamerman[SUP] 6 [/SUP], Neil P King[SUP] 5 [/SUP], Michael Gale Jr[SUP] 4 [/SUP], Daniel J Campbell[SUP] 6 [/SUP], David J Rawlings[SUP] 7 [/SUP], Marion Pepper[SUP] 8 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a global pandemic, and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. We performed a longitudinal assessment of individuals recovered from mild COVID-19 to determine whether they develop and sustain multifaceted SARS-CoV-2-specific immunological memory. Recovered individuals developed SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B and memory T cells that persisted for at least 3 months. Our data further reveal that SARS-CoV-2-specific IgG memory B cells increased over time. Additionally, SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral function: memory T cells secreted cytokines and expanded upon antigen re-encounter, whereas memory B cells expressed receptors capable of neutralizing virus when expressed as monoclonal antibodies. Therefore, mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks of antiviral immunity.

Keywords: COVID-19; SARS-CoV2; adaptive immune response; human; memory B cell; memory T cell; monoclonal antibody; vaccine.
 
Back
Top Bottom